Methods and compositions for treating diseases and disorders of the nervous system
AssigneeRutgers, The State University of New Jersey
InventorsHannah E. BOWREY, Gary ASTON-JONES
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.
Claims24
A method of treating a disease or disorder of the nervous system in a subject, comprising the steps of:
- a. administering an effective amount of a viral vector to the eye of the subject, wherein the viral vector comprises a promoter, a DREADD, and a 3′ untranslated region encoded by the nucleotide sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:10;
- b. expressing the DREADD of step (a) prior to administration of an agonist to the DREADD;
- and
- c. administering to the subject an agonist to the expressed DREADD.
A method of treating a disease or disorder of the nervous system in a subject, comprising the steps of:
- a. administering an effective amount of a viral vector to the subject, wherein the viral vector comprises a promoter, a DREADD, and a 3′ untranslated region encoded by the nucleotide sequence SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID:11;
- b. expressing the DREADD of step (a) prior to administration of an agonist to the DREADD;
- and
- c. administering to the subject an agonist to the expressed DREADD.
22-25. (canceled)
An isolated nucleic acid promoter comprising SEQ ID NO:5, a fragment of SEQ ID NO:5, or a variant of SEQ ID NO:
- 5 having at least about 75% identity to SEQ ID NO:
- 5, that retains promoter activity in retinal cells.
A kit comprising a viral vector, wherein the viral vector comprises a promoter, a DREADD, and a 3′ untranslated region encoded by the nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, and an agonist to the DREADD.
Dependencies are inferred from the claim text.